DK0871474T3 - Generering af humant insulin - Google Patents

Generering af humant insulin

Info

Publication number
DK0871474T3
DK0871474T3 DK95907193T DK95907193T DK0871474T3 DK 0871474 T3 DK0871474 T3 DK 0871474T3 DK 95907193 T DK95907193 T DK 95907193T DK 95907193 T DK95907193 T DK 95907193T DK 0871474 T3 DK0871474 T3 DK 0871474T3
Authority
DK
Denmark
Prior art keywords
human insulin
folded
polypeptide
insulin generation
new
Prior art date
Application number
DK95907193T
Other languages
English (en)
Other versions
DK0871474T4 (da
Inventor
Jacob R Hartman
Simona Mendelovitz
Marian Gorecki
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22243290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0871474(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Application granted granted Critical
Publication of DK0871474T3 publication Critical patent/DK0871474T3/da
Publication of DK0871474T4 publication Critical patent/DK0871474T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DK95907193.7T 1994-12-29 1994-12-29 Fremstilling af human insulin DK0871474T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/013268 WO1996020724A1 (en) 1994-12-29 1994-12-29 Generation of human insulin

Publications (2)

Publication Number Publication Date
DK0871474T3 true DK0871474T3 (da) 2007-05-07
DK0871474T4 DK0871474T4 (da) 2012-01-09

Family

ID=22243290

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907193.7T DK0871474T4 (da) 1994-12-29 1994-12-29 Fremstilling af human insulin

Country Status (15)

Country Link
EP (1) EP0871474B2 (da)
JP (1) JP4624495B2 (da)
AT (1) ATE350053T1 (da)
AU (1) AU698872B2 (da)
BR (1) BR9408638A (da)
CA (1) CA2208095C (da)
CZ (1) CZ290079B6 (da)
DE (2) DE69434909T3 (da)
DK (1) DK0871474T4 (da)
ES (1) ES2279510T5 (da)
HU (1) HU223718B1 (da)
NZ (1) NZ279002A (da)
PL (1) PL180818B1 (da)
PT (1) PT871474E (da)
WO (1) WO1996020724A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
US6924120B1 (en) 1998-03-31 2005-08-02 Tonghua Gantech Biotechnology, Ltd. Chaperone protein containing an intramolecular chaperone-like sequence and its application to insulin production
JP3406244B2 (ja) 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
DK1265630T3 (da) 2000-03-24 2006-10-09 Genentech Inc Anvendelse af insulin til behandling af brusksygdomme
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE60138572D1 (de) 2000-07-31 2009-06-10 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ES2306981T3 (es) 2003-01-31 2008-11-16 N.V. Organon Metodo para aislamiento de proteinas en condiciones anoxicas.
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US9074015B2 (en) * 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012048856A1 (en) 2010-10-12 2012-04-19 Glucometrix Pvs Gmbh Proinsulin with helper sequence
WO2012098009A1 (en) 2011-01-21 2012-07-26 Glucometrix Ag Chimeric polypeptide comprising a membrane protein and an insulin precursor
EP2867250A2 (en) 2012-04-04 2015-05-06 GlucoMetrix AG Proinsulin with enhanced helper sequence
CA2866491A1 (en) * 2014-10-02 2016-04-02 Clay Purdy Synthetic acid compositions and uses thereof
EP3341405A4 (en) * 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROCESS FOR INSULIN PRODUCTION
PL239062B1 (pl) * 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
BR112019004314A2 (pt) * 2016-09-06 2019-05-28 Chemical & Biopharmaceutical Laboratories Of Patras S A derivados pró-insulina
BR112019005637A2 (pt) * 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
JP2021532730A (ja) * 2018-06-18 2021-12-02 ユニケム ラボラトリーズ リミテッド 組換えタンパク質の発現レベルを高めるためのリーダー配列
CN112584853B (zh) * 2018-09-12 2021-12-10 美药星（南京）制药有限公司 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法
CN113226284B (zh) 2018-09-25 2024-12-03 美药星制药股份有限公司 高度纯化的重组人胰岛素（rhi）api及其生产方法
CN113527505A (zh) * 2020-04-15 2021-10-22 博锐生物科技有限公司 一种多肽和包含该多肽的药物组合物以及它们的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430266A (en) * 1980-11-28 1984-02-07 Eli Lilly And Company Process for producing an insulin precursor
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
CA1260858A (en) † 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
DE3901719A1 (de) * 1989-01-21 1990-07-26 Hoechst Ag Verfahren zur herstellung eines insulinvorlaeufers
DE3901718A1 (de) * 1989-01-21 1990-07-26 Hoechst Ag Verfahren zur renaturierung falscher rekombinanten von insulinvorlaeufern
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
IL104727A (en) * 1992-02-18 1997-01-10 Lilly Co Eli Selective removal of n-terminal extensions from folded insulin precursors using dipeptidyl-aminopeptidase-1
DE19701167A1 (de) * 1997-01-15 1998-07-23 Siemens Ag Chipkarte

Also Published As

Publication number Publication date
EP0871474A4 (en) 2004-08-18
AU698872B2 (en) 1998-11-12
CA2208095A1 (en) 1996-07-11
DE69434909D1 (de) 2007-02-15
ES2279510T5 (es) 2012-01-19
NZ279002A (en) 1999-02-25
ATE350053T1 (de) 2007-01-15
DE69434909T3 (de) 2012-02-09
EP0871474B1 (en) 2007-01-03
PL180818B1 (pl) 2001-04-30
HU223718B1 (hu) 2004-12-28
EP0871474B2 (en) 2011-09-21
PL321039A1 (en) 1997-11-24
DK0871474T4 (da) 2012-01-09
HUT78070A (hu) 1999-08-30
EP0871474A1 (en) 1998-10-21
CZ203197A3 (cs) 1998-09-16
BR9408638A (pt) 2004-09-21
WO1996020724A1 (en) 1996-07-11
JP4624495B2 (ja) 2011-02-02
CZ290079B6 (cs) 2002-05-15
DE95907193T1 (de) 2005-02-10
PT871474E (pt) 2007-02-28
CA2208095C (en) 2006-11-28
JPH10511849A (ja) 1998-11-17
ES2279510T3 (es) 2007-08-16
HK1013594A1 (en) 1999-09-03
AU1550095A (en) 1996-07-24
DE69434909T2 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
DK0871474T4 (da) Fremstilling af human insulin
DE69526636D1 (de) Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
DK0542863T3 (da) Ekspression af rekombinante polypeptider med forbedret oprensning
ES2124295T3 (es) Expresion y purificacion de factor tisular soluble recombinante.
DK1005526T3 (da) Direkte ekspression af peptider i kulturmedium
DE3855536D1 (de) Rezeptoren für wachstumshormone
ES2075155T3 (es) Separacion enzimatica de una secuencia de una proteina con amino terminal.
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
KR880700076A (ko) 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
EP0330506A3 (en) Vla proteins
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
ES536027A0 (es) Un procedimiento para la produccion de un polipeptido
AU580348B2 (en) A process for the cleavage of peptides and proteins at the methionyl bond
Benya EC collagen: biosynthesis by corneal endothelial cells and separation from type IV without pepsin treatment or denaturation
EP0269455A3 (en) Highly purified fused protein comprising human ige fc fragment and production thereof
JPS646219A (en) Peptide having promoting action on activation of protein c by thrombin
ES2062759T3 (es) Procedimiento de purificacion de polipeptidos recombinantes.
ES2310055T3 (es) Quinasa humana dependiente de ciclina (hpnqalre).
PE70698A1 (es) Proteina quimerica de union a tnfo para el tratamiento del asma
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer